MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-27-2026
Inogen Total Assets 2011-2026 | INGN
Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.Main categories of assets
Current assets (used within one year):
- Cash and cash equivalents
- Accounts receivable (amounts owed by customers)
- Inventory of goods, raw materials, and supplies
- Short-term investments
- Fixed assets (buildings, machinery, equipment)
- Intangible assets (brands, patents, software)
- Long-term investments
- Goodwill (reputational value from mergers)
Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.
Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.
Annual Total Assets Inogen
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 299 M | 296 M | 326 M | 405 M | 490 M | 462 M | 447 M | 376 M | 275 M | 214 M | 161 M | 140 M | 82.4 M | 47.6 M | 24.1 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 490 M | 24.1 M | 270 M |
Quarterly Total Assets Inogen
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 307 M | 312 M | 308 M | 296 M | 306 M | 309 M | 316 M | 326 M | 344 M | 374 M | 386 M | 405 M | 470 M | - | 475 M | 490 M | 513 M | 498 M | 476 M | 462 M | 462 M | 462 M | 462 M | 447 M | 447 M | 447 M | 447 M | 376 M | 376 M | 376 M | 376 M | 275 M | 275 M | 275 M | 275 M | 214 M | 214 M | 214 M | 214 M | 161 M | 161 M | 161 M | 161 M | 140 M | 140 M | 140 M | 140 M | 82.4 M | 82.4 M | 82.4 M | 82.4 M | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 513 M | 82.4 M | 311 M |
Total Assets of other stocks in the Medical devices industry
| Issuer | Total Assets | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Align Technology
ALGN
|
6.21 B | $ 191.66 | 0.84 % | $ 14.4 B |  USA |
 |
Axonics Modulation Technologies
AXNX
|
659 M | - | - | $ 3.31 B | USA |
 |
GenMark Diagnostics, Inc.
GNMK
|
224 M | - | - | $ 1.77 B | USA |
 |
Acutus Medical
AFIB
|
54 M | - | -26.83 % | $ 2.62 M | USA |
 |
Aziyo Biologics
AZYO
|
62.4 M | - | 1.37 % | $ 20.5 M | USA |
 |
Avinger
AVGR
|
13.8 M | - | -20.74 % | $ 369 K | USA |
 |
AdaptHealth Corp.
AHCO
|
4.32 B | $ 12.67 | 0.08 % | $ 1.71 B | USA |
 |
BIOLASE
BIOL
|
35.1 M | - | -13.19 % | $ 166 K | USA |
 |
Allied Healthcare Products
AHPI
|
19.7 M | - | 3.58 % | $ 2.21 M | USA |
 |
BioSig Technologies
BSGM
|
188 M | - | 37.08 % | $ 85.7 M | USA |
 |
Obalon Therapeutics, Inc.
OBLN
|
10.6 M | - | -5.86 % | $ 30.6 M | USA |
 |
Conformis
CFMS
|
94 M | - | - | $ 16.4 M | USA |
 |
EDAP TMS S.A.
EDAP
|
86.1 M | $ 3.42 | -2.01 % | $ 128 M |  France |
 |
Cardiovascular Systems
CSII
|
323 M | - | 0.15 % | $ 844 M | USA |
 |
Boston Scientific Corporation
BSX
|
43.7 B | $ 60.99 | -5.03 % | $ 90.3 B | USA |
 |
Apollo Endosurgery
APEN
|
110 M | - | - | $ 475 M | USA |
 |
Cytosorbents Corporation
CTSO
|
44.2 M | $ 0.65 | -2.26 % | $ 40.5 M | USA |
 |
Dynatronics Corporation
DYNT
|
15.4 M | - | 14.99 % | $ 929 K | USA |
 |
Eargo
EAR
|
132 M | - | - | $ 10.2 M | USA |
 |
ClearPoint Neuro
CLPT
|
97.7 M | $ 11.16 | -5.34 % | $ 316 M | USA |
 |
CryoLife, Inc.
CRY
|
789 M | - | -4.14 % | $ 702 M | USA |
 |
Electromed
ELMD
|
53.8 M | $ 25.4 | -2.53 % | $ 215 M | USA |
 |
GBS
GBS
|
8.25 M | - | -0.57 % | $ 7.12 M | USA |
 |
Second Sight Medical Products
EYES
|
39.4 M | - | -0.97 % | $ 54.4 M | USA |
 |
Soliton, Inc.
SOLY
|
33.8 M | - | -1.42 % | $ 435 M | USA |
 |
Hancock Jaffe Laboratories, Inc.
HJLI
|
10.5 K | - | -1.98 % | $ 98.3 M | USA |
 |
Itamar Medical Ltd.
ITMR
|
64.1 M | - | 0.03 % | $ 1.58 B |  Israel |
 |
Misonix, Inc.
MSON
|
204 M | - | - | $ 462 M | USA |
 |
Neovasc
NVCN
|
66.2 M | - | - | $ 111 M |  Canada |
 |
IRIDEX Corporation
IRIX
|
29.2 M | $ 1.05 | -0.94 % | $ 17.8 M | USA |
 |
Globus Medical
GMED
|
5.3 B | $ 96.82 | 1.65 % | $ 13.1 B | USA |
 |
Butterfly Network
BFLY
|
256 M | $ 5.49 | 0.73 % | $ 1.16 B | USA |
 |
Intersect ENT, Inc.
XENT
|
227 M | - | - | $ 955 M | USA |
 |
Helius Medical Technologies
HSDT
|
7.69 M | $ 2.12 | - | $ 1.29 M | USA |
 |
Delcath Systems
DCTH
|
124 M | $ 10.88 | 0.18 % | $ 390 M | USA |
 |
LivaNova PLC
LIVN
|
2.61 B | $ 65.81 | -1.95 % | $ 3.59 B |  Britain |
 |
Inspire Medical Systems
INSP
|
907 M | $ 56.97 | -1.08 % | $ 1.67 B | USA |
 |
CONMED Corporation
CNMD
|
2.33 B | $ 39.68 | 1.54 % | $ 1.23 B | USA |
 |
Integer Holdings Corporation
ITGR
|
3.41 B | $ 89.32 | -0.98 % | $ 3.1 B | USA |
 |
OrthoPediatrics Corp.
KIDS
|
509 M | $ 16.65 | -0.6 % | $ 391 M | USA |
 |
FONAR Corporation
FONR
|
199 M | $ 18.8 | - | $ 123 M | USA |
 |
Invacare Corporation
IVC
|
771 M | - | - | $ 24.7 M | USA |
 |
Edwards Lifesciences Corporation
EW
|
13.7 B | $ 81.44 | 0.56 % | $ 47.6 B | USA |
 |
LENSAR
LNSR
|
71.4 M | $ 5.55 | -6.41 % | $ 66.4 M | USA |
 |
Cutera
CUTR
|
346 M | - | -10.19 % | $ 1.99 M | USA |
 |
Myomo
MYO
|
38.6 M | $ 0.9 | 4.73 % | $ 37.7 M | USA |
 |
Smith & Nephew plc
SNN
|
10.5 B | $ 34.21 | -0.44 % | $ 23.8 B | Britain |